MOH Research Note — The Cost Ratio Test
Molina’s cash flow supports the recovery case, while Marketplace losses and the October medical-cost test keep conviction limited.
MOH
MOH Deep Coverage Review — Analysis as of August 10, 2026
Molina’s cash flow and long-term structure support recovery, but Marketplace losses and Medicaid policy pressure leave little room for error.
MOH Research Note — Medical Costs Stay Unresolved
Molina's raised outlook faces a 92.2% medical-cost ratio, a 57% ACA membership decline and weak price structure.
MOH Deep Coverage Review — Analysis as of August 3, 2026
Molina's earnings beat faces a 92.2% medical-cost ratio, a 57% ACA membership decline and unresolved valuation evidence.
MOH Research Note — The Beat Masks Strain
Molina’s earnings beat and raised outlook face a harder test from weak premium revenue, declining membership and sharply compressed margins.
MOH Deep Coverage Review — Analysis as of July 27, 2026
Molina’s earnings beat masks weaker premium revenue, declining membership and compressed margins while the shares lag a strong health-care tape.